Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 368
5
Diseases
74
Unique genes
0.176
Avg. similarity score
Liver failure
Most-connected disease (4 links)
Disease
Searched: Dihydropteridine reductase deficiency
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Dihydropteridine reductase deficiency
Liver failure
Diabetic angiopathies
Diabetic peripheral angiopathy
autoimmune lymphoproliferative syndrome type 1
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Liver failure | 4 | 4 | 52 |
| Diabetic angiopathies | 3 | 3 | 28 |
| Diabetic peripheral angiopathy | 3 | 3 | 28 |
| autoimmune lymphoproliferative syndrome type 1 | 3 | 3 | 1 |
| Dihydropteridine reductase deficiency | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| FASLG | 4 / 5 | autoimmune lymphoproliferative syndrome type 1, Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| ALB | 3 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| ASS1 | 3 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| IL1RN | 3 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| TNF | 3 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| VEGFA | 3 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy, Liver failure |
| ADCY3 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| ADCY8 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| AGER | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| CASP3 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| CREM | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| CXCL12 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| EPO | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| GCH1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| HLA-DRB1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| HMOX1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| HP | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| IGFBP1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| MTHFR | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| NOS3 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| PLAT | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| PON1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| QDPR | 2 / 5 | Dihydropteridine reductase deficiency, Liver failure |
| RELA | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| SERPINE1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| SERPINF1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| SOD2 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| THBS1 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
| THBS2 | 2 / 5 | Diabetic angiopathies, Diabetic peripheral angiopathy |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Alcoholic liver disease | KEGG | 10 / 144 | 11.3× | 1.67e-8 | 1.44e-6 ✓ sig. |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 8 / 101 | 12.9× | 1.80e-7 | 1.17e-5 ✓ sig. |
| HIF-1 signaling pathway | KEGG | 8 / 110 | 11.8× | 3.50e-7 | 2.09e-5 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 8 / 141 | 9.2× | 2.32e-6 | 1.08e-4 ✓ sig. |
| Non-alcoholic fatty liver disease | KEGG | 8 / 157 | 8.3× | 5.18e-6 | 2.08e-4 ✓ sig. |
| Lipid and atherosclerosis | KEGG | 9 / 216 | 6.8× | 6.69e-6 | 2.56e-4 ✓ sig. |
| Type I diabetes mellitus | KEGG | 5 / 44 | 18.4× | 6.97e-6 | 2.65e-4 ✓ sig. |
| Human cytomegalovirus infection | KEGG | 9 / 226 | 6.5× | 9.64e-6 | 3.44e-4 ✓ sig. |
| Malaria | KEGG | 5 / 50 | 16.2× | 1.32e-5 | 4.46e-4 ✓ sig. |
| Pathways in cancer | KEGG | 13 / 533 | 4.0× | 1.95e-5 | 6.16e-4 ✓ sig. |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | Reactome | 3 / 10 | 48.7× | 2.61e-5 | 7.88e-4 ✓ sig. |
| Chagas disease | KEGG | 6 / 103 | 9.5× | 3.97e-5 | 1.11e-3 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 6 / 108 | 9.0× | 5.19e-5 | 1.38e-3 ✓ sig. |
| Glycolysis / Gluconeogenesis | KEGG | 5 / 67 | 12.1× | 5.56e-5 | 1.46e-3 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 10 / 361 | 4.5× | 6.89e-5 | 1.73e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| response to hypoxia | GO:0001666 | 11 / 176 | 15.8× | 9.45e-11 | 2.76e-8 ✓ sig. |
| acute-phase response | GO:0006953 | 7 / 37 | 47.8× | 1.07e-10 | 3.10e-8 ✓ sig. |
| response to lipopolysaccharide | GO:0032496 | 9 / 161 | 14.1× | 1.43e-8 | 2.33e-6 ✓ sig. |
| response to nutrient levels | GO:0031667 | 7 / 79 | 22.4× | 2.64e-8 | 3.97e-6 ✓ sig. |
| extrinsic apoptotic signaling pathway | GO:0097191 | 6 / 57 | 26.6× | 9.70e-8 | 1.20e-5 ✓ sig. |
| negative regulation of fibrinolysis | GO:0051918 | 4 / 12 | 84.2× | 1.09e-7 | 1.33e-5 ✓ sig. |
| response to hydrogen peroxide | GO:0042542 | 5 / 39 | 32.4× | 4.40e-7 | 4.32e-5 ✓ sig. |
| liver development | GO:0001889 | 6 / 87 | 17.4× | 1.23e-6 | 1.00e-4 ✓ sig. |
| positive regulation of ERK1 and ERK2 cascade | GO:0070374 | 8 / 201 | 10.1× | 1.28e-6 | 1.04e-4 ✓ sig. |
| vasodilation | GO:0042311 | 5 / 50 | 25.3× | 1.57e-6 | 1.23e-4 ✓ sig. |
| response to amino acid | GO:0043200 | 4 / 22 | 45.9× | 1.57e-6 | 1.23e-4 ✓ sig. |
| negative regulation of plasminogen activation | GO:0010757 | 3 / 7 | 108× | 2.06e-6 | 1.52e-4 ✓ sig. |
| positive regulation of cell migration | GO:0030335 | 9 / 292 | 7.8× | 2.23e-6 | 1.63e-4 ✓ sig. |
| positive regulation of canonical NF-kappaB signal transduction | GO:0043123 | 8 / 232 | 8.7× | 3.73e-6 | 2.44e-4 ✓ sig. |
| tumor necrosis factor-mediated signaling pathway | GO:0033209 | 5 / 60 | 21.0× | 3.91e-6 | 2.54e-4 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Diabetic angiopathies | Diabetic peripheral angiopathy | 0.966 | 28 | 1.76e-88 | 1.55e-86 ✓ sig. |
| Diabetic angiopathies | Liver failure | 0.080 | 6 | 3.92e-10 | 3.69e-9 ✓ sig. |
| Diabetic peripheral angiopathy | Liver failure | 0.080 | 6 | 3.92e-10 | 3.69e-9 ✓ sig. |
| autoimmune lymphoproliferative syndrome type 1 | Diabetic angiopathies | 0.034 | 1 | 1.82e-3 | 2.68e-3 ✓ sig. |
| autoimmune lymphoproliferative syndrome type 1 | Diabetic peripheral angiopathy | 0.034 | 1 | 1.82e-3 | 2.68e-3 ✓ sig. |
| autoimmune lymphoproliferative syndrome type 1 | Liver failure | 0.019 | 1 | 3.38e-3 | 4.37e-3 ✓ sig. |
| Dihydropteridine reductase deficiency | Liver failure | 0.019 | 1 | 3.38e-3 | 4.37e-3 ✓ sig. |